News

Zepbound Outperforms Wegovy in Head-to-Head Weight Loss Study
Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both ...
Zepbound beats Wegovy for weight loss in trial of blockbuster drugs
Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...
Hosted on MSN5d
Eli Lilly's Zepbound Outperforms Wegovy In New Obesity Trial, But Trump's Drug Pricing Plan Keeps Retail Traders Wary
Eli Lilly and Co's obesity drug Zepbound led to greater weight loss than Novo Nordisk's Wegovy in a head-to-head ...
Battle of the weight loss blockbuster drugs: Zepbound beats Wegovy by nearly 50%
Participants who took tirzepatide — which is sold as Zepbound by Eli Lilly — lost an average of 50 pounds over 72 weeks.
Why Patients Are Being Forced to Switch to a 2nd-Choice Obesity Drug
CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...
Do Medicare, Medicaid cover weight loss drugs? It depends
Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.